PTC Therapeutics, Inc. (PTCT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

PTC Therapeutics, Inc. (PTCT) is down 10.2% since the beginning of the year. At $68 per share, PTCT is trading 22.0% below its 52-week high of $88. Investors who bought $1,000 worth of PTCT shares 5 years ago would now be looking at an investment worth $1,773.

PTC Therapeutics, Inc. (PTCT) has returned -10.18% so far this year and 34.60% over the past 12 months. Looking at the last ten years, PTCT has achieved an annualized return of 24.46%, outperforming the S&P 500 Index benchmark, which averaged 13.75% per year.

Based on dividend-adjusted daily data since Jun 20, 2013, PTCT's average daily return is +0.15%, while the average monthly return is +2.77%. At this rate, an investment would double in approximately 2.1 years.

Historically, 55% of months were positive and 45% were negative. The best month was Nov 2016 with a return of +79.4%, while the worst month was Feb 2016 at -66.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, PTCT closed higher 50% of trading days. The best single day was Nov 11, 2016 with a return of +88.3%, while the worst single day was Feb 23, 2016 at -61.6%.

PTC Therapeutics, Inc. has an annualized alpha of 24.77%, beta of 1.22, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since June 21, 2013.

• This stock participated in 127.52% of S&P 500 Index downside but only 119.78% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PTCT ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for PTC Therapeutics, Inc. (PTCT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the PTC Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the PTC Therapeutics, Inc. was 94.60%, occurring on Nov 3, 2016. Recovery took 2275 trading sessions.

The current PTC Therapeutics, Inc. drawdown is 20.89%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of PTC Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how PTC Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.